WAYNE, Pa.--(BUSINESS WIRE)--Advances in the availability and reproducibility of monoclonal antibody reagents specific for a wide range of cell types, coupled with lower costs for increasingly automated flow cytometers with greater data analysis capabilities, have made flow cytometry the method of choice for immunophenotyping hematopoietic cells in the clinical laboratory. The newly published edition of Clinical and Laboratory Standards Institute’s (CLSI, formerly NCCLS) document, Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline—Second Edition (H42-A2), addresses issues of procedures and quality assurance for clinical applications of flow cytometry. It is designed to aid clinical laboratorians in the development of quality assurance procedures and to establish the foundation for different laboratories using different commercially available instruments to obtain comparable results.
